What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 10, 2015, Pages 1127-1136

  Karaszewski, Bartosz ^a,b   Houlden, Henry ^a   Smith, Eric E ^c   Markus, Hugh S ^d   Charidimou, Andreas ^a   Levi, Christopher ^e   Werring, David J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLASMINOGEN; RETEPLASE; TENECTEPLASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FIBRINOLYSIS; GENE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TPA GENE; ADVERSE EFFECTS; CEREBRAL HEMORRHAGE; COMPLICATION; FIBRINOLYTIC THERAPY; STROKE;

BIOMARKERS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; STROKE; THROMBOLYTIC THERAPY;

EID: 84942098230     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309705     Document Type: Article

References (106)

1. Sandercock P, Wardlaw JM, Lindley RI, et al., IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352-63. Erratum in: Lancet 2012;380:730.
2. Hacke W, Kaste M, Bluhmki E, et al., ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
3. Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276 g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000;31:811-16.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
5. Davis SM, Donnan GA, Parsons MW, et al., EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.
6. Brown SG, Macdonald SP, Hankey GJ. Do risks outweigh benefits in thrombolysis for stroke? BMJ 2013;347:f5215.
7. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 2008;79:1093-9.
8. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and metaanalysis. Lancet 2012;379:2364-72.
9. Whiteley WN, Slot KB, Fernandes P, et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012;43:2904-9.
10. Whiteley WN, Thompson D, Murray G, et al., IST-3 Collaborative Group. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial. Stroke 2014;45:1000-6.
11. Strbian D, Michel P, Seiffge DJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores. Stroke 2014;45:752-8.
12. Ohman EM, Granger CB, Harrington RA, et al. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 2000;284:876-8.
13. Wang X, Tsuji K, Lee SR, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35(11 Suppl 1):2726-30.
14. Sherry S. Fibrinolysis, thrombosis and hemostasis. Concepts, perspectives and clinical applications. Philadelphia, PA: Lea and Febiger, 1992:1-318.
15. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005;93:655-60.
16. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 2005;25:2470-9.
17. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-19.
18. Khatri R, McKinney AM, Swenson B, et al. Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology 2012;79(13 Suppl 1):S52-7.
19. Salame MY, Samani NJ, Masood I, et al. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 2000;152:19-28.
20. Padro T, Emeis JJ, Steins M, et al. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995;15:893-902.
21. Steins MB, Padro T, Li CX, et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 1999;145:173-80.
22. Yepes M, Roussel BD, Ali C, et al. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009;32:48-55.
23. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010;38:376-85.
24. Lopez-Atalaya JP, Roussel BD, Levrat D, et al. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab 2008;28:1212-21.
25. Shi GY, Hau JS, Wang SJ, et al. Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells. J Biol Chem 1992;267:19363-8.
26. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987;109:97-104.
27. Naess H, Idicula T, Lagallo N, et al. Inverse relationship of baseline body temperature and outcome between ischemic stroke patients treated and not treated with thrombolysis: the Bergen stroke study. Acta Neurol Scand 2010;122:414-17.
28. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation. Thromb Res 2012;129:314-19.
29. Morser J, Gabazza EC, Myles T, et al. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 2010;8:868-76.
30. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-64.
31. Witherow FN, Dawson P, Ludlam CA, et al. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol 2002;40:961-6.
32. Mehta RH, Cox M, Smith EE, et al., Get With The Guidelines-Stroke Program. Race/ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke 2014;45:2263-9.
33. Tjärnlund-Wolf A, Brogren H, Lo EH, et al. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke 2012;43:2833-9.
34. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010;28:e72-91.
35. Chandler WL, Trimble SL, Loo SC, et al. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990;76:930-7.
36. Nagai N, Van Hoef B, Lijnen HR. Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice. J Thromb Haemost 2007;5:1726-31.
37. Lip GY, Blann AD. Does hypertention confere a prothrombotic state? Virchow's triad revisited. Circulation 2000;101:218-20.
38. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007;262:157-72.
39. Lindgren A, Lindoff C, Norrving B, et al. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996;27:1066-71.
40. Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000;31:26-32.
41. Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol 1996;16:1277-84.
42. Narita M, Bu G, Herz J, et al. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest 1995;96:1164-8.
43. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008;122:736-42.
44. Jeppesen LL, Wilhelmsen K, Nielsen LB, et al. An Insertion/deletion polymorphism in the promoter region of the plasminogen activator inhibitor-1 gene is associated with plasma levels but not with stroke risk in the elderly. J Stroke Cerebrovasc Dis 1998;7:385-90.
45. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost 2007;5:1862-8.
46. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis 2007;18:497-504.
47. Ladenvall C, Gils A, Jood K, et al. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007;27:955-62.
48. Fernández-Cadenas I, Molina C, Alvarez-Sabín J, et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci Lett 2006;398:167-71.
49. Gonzalez-Conejero R, Fernandez-Cadenas I, Iniesta J, et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 2006;37:2288-93.
50. Sun X, Lai R, Li J, et al. The -7351C/T polymorphism in the TPA gene and ischemic stroke risk: a meta-analysis. PLoS ONE 2013;8:e53558.
51. Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012;11:951-62.
52. Babu MS, Prabha TS, Kaul S, et al. Association of genetic variants of fibrinolytic system with stroke and stroke subtypes. Gene 2012;495:76-80.
53. Markus HS, Bevan S. Mechanisms and treatment of ischaemic stroke-insights from genetic associations. Nat Rev Neurol 2014;10:723-30.
54. Ross S, Paré G. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. Pharmacogenomics 2013;14: 1565-72.
55. Thanvi BR, Treadwell S, Robinson T. Heamorrhagic transformation in acute ischaemic stroke following thrombolysis therapy: classification, pathogenesis and risk factors. Postgrad Med J 2008;84:361-7.
56. Larrue V, von Kummer RR, Müller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41.
57. Renou P, Sibon I, Tourdias T, et al. Reliability of the ECASS radiological classification of postthrombolysis brain haemorrhage: a comparison of CT and three MRI sequences. Cerebrovasc Dis 2010;29:597-604.
58. Strbian D, Sairanen T, Meretoja A, et al., Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis.Neurology 2011;77:341-8.
59. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999;30:2280-4.
60. Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951;10:92.
61. Terruso V, D'Amelio M, Di Benedetto N, et al. Frequency and determinants of hemorrhagic transformation of cerebral infarction. Neuroepidemiology 2009;33:261-5.
62. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40-6.
63. Hu B, Liu C, Zivin JA. Reduction of intracerebral hemorrhage in a rabbit embolic stroke model. Neurology 1999;53:2140-5.
64. Asahi M, Asahi K, Wang X, et al. Reduction of tissue plasminogen activator induced hemorrhage and brain injury by free radical spin trapping after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20:452-7.
65. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPS are associated with blood brain barrier opening after reperfusion in rat brain. Stroke 1998;29:2189-95.
66. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knockout on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724-32.
67. Choi KH, Park MS, Kim JT, et al. The serum ferritin level is an important predictor of hemorrhagic transformation in acute ischaemic stroke. Eur J Neurol 2012;19:570-7.
68. Vo KD, Santiago F, Lin W, et al. MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. AJNR Am J Neuroradiol 2003;24:674-9.
69. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-6.
70. Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998;29:1020-30.
71. Wang X, Lo EH. Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol Neurobiol 2003;28:229-44.
72. Borlongan CV. The blood brain barrier in stroke. Curr Pharm Des 2012;18:3613-14.
73. Fisher M, Albers GW. Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Ann Neurol 2013;73:4-9.
74. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
75. Ahmed N, Wahlgren N, Grond M, et al., SITS investigators. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74.
76. Mazya MV, Ahmed N, Ford GA, et al. Remote or extraischemic intracerebral hemorrhage - an uncommon complication of stroke thrombolysis: results from the safe implementation of treatments in stroke-International Stroke Thrombolysis Register. Stroke 2014;45:1657-63.
77. Trouillas P, Derex L, Philippeau F, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke 2004;35:1323-8.
78. McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 2004;3:484-92.
79. Winkler DT, Biedermann L, Tolnay M, et al. Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. Ann Neurol 2002;51:790-3.
80. Knudsen KA, Rosand J, Karluk D, et al. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537-9.
81. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689-701.
82. Charidimou A, Werring DJ. Cerebral microbleeds: detection, mechanisms and clinical challenges. Future Neurology 2011;6:587-611.
83. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165-74.
84. Charidimou A, Kakar P, Fox Z, et al. Cerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2013;84:277-80.
85. Jeon SB, Kwon SU, Cho AH, et al. Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology 2009;73:1638-44.
86. Kimura K, Aoki J, Shibazaki K, et al. New appearance of extraischemic microbleeds on T2∗-weighted magnetic resonance imaging 24 hours after tissue-type plasminogen activator administration. Stroke 2013;44:2776-81.
87. Rannikmäe K, Kalaria RN, Greenberg SM, et al. APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry 2014;85:300-5.
88. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al., MR Stroke Group. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006;37:2463-6.
89. Palumbo V, Boulanger JM, Hill MD, et al., CASES Investigators. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007;68:1020-4.
90. Ariës MJH, Uyttenboogaart M, Vroomen PC, et al. tPA treatment for acute ischaemic stroke in patients with leukoaraiosis. Eur J Neurol 2010;17:866-70.
91. Shi ZS, Loh Y, Liebeskind DS, et al. Leukoaraiosis predicts parenchymal hematoma after mechanical thrombectomy in acute ischemic stroke. Stroke 2012;43:1806-11.
92. Demchuk AM, Khan F, Hill MD, et al. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis 2008;26:120-5.
93. Dzialowski I, Hill MD, Coutts SB, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006;37:973-8.
94. Singer OC, Kurre W, Humpich MC, et al., MR Stroke Study Group Investigators. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS. Stroke 2009;40:2743-8.
95. Latour LL, Kang DW, Ezzeddine MA, et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004;56:468-77.
96. Hermier M, Nighoghossian N, Derex L, et al. Hypointense transcerebral veins at T2∗-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab 2003;23:1362-70.
97. Campbell BC, Christensen S, Parsons MW, et al., EPITHET and DEFUSE Investigators. Advanced imaging improves prediction of hemorrhage after stroke thrombolysis. Ann Neurol 2013;73:510-19.
98. Hom J, Dankbaar JW, Soares BP, et al. Blood-brain barrier permeability assessed by perfusion CT predicts symptomatic hemorrhagic transformation and malignant edema in acute ischemic stroke. AJNR Am J Neuroradiol 2011;32:41-8.
99. Aviv RI, d'Esterre CD, Murphy BD, et al. Hemorrhagic transformation of ischemic stroke: prediction with CT perfusion. Radiology 2009;250:867-77.
100. Bang OY, Buck BH, Saver JL, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2∗-permeability magnetic resonance imaging. Ann Neurol 2007;62:170-6.
101. Bisdas S, Hartel M, Cheong LH, et al. Prediction of subsequent hemorrhage in acute ischemic stroke using permeability CT imaging and a distributed parameter tracer kinetic model. J Neuroradiol 2007;34:101-8.
102. Kassner A, Roberts T, Taylor K, et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol 2005;26:2213-17.
103. Karaszewski B, Thomas RG, Chappell FM, et al. Brain choline concentration: early quantitative marker of ischemia and infarct expansion? Neurology 2010;75:850-6.
104. Karaszewski B, Wardlaw JM, Marshall I, et al. Early brain temperature elevation and anaerobic metabolism in human acute ischaemic stroke. Brain 2009;132:955-64.
105. Karaszewski B, Carpenter TK, Thomas RG, et al. Relationships between brain and body temperature, clinical and imaging outcomes after ischemic stroke. J Cereb Blood Flow Metab 2013;33:1083-9.
106. Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 2010;41:288-94.